

Global Infectious Disease Point of Care Diagnostics Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

<https://marketpublishers.com/r/G936D8BECC7EN.html>

Date: November 2017

Pages: 211

Price: US\$ 4,400.00 (Single User License)

ID: G936D8BECC7EN

Abstracts

Point of care diagnostics refers to the tests carried at site of the patient care to provide the immediate results. These diagnostics improve the disease management and detection. Infectious diseases are caused by various microorganisms such as virus, bacteria, fungi, and parasites. Infectious disease point of care diagnostics reduces the time between disease testing and diagnosis of an infection. Nowadays most of the infectious diseases such as HIV, tuberculosis, influenza, tropical diseases, and sexually transmitted infections are diagnosed by the point of care testing. The major advantages with the point of care testing are reduced in diagnosis time, postoperative care time, improvement in disease outcomes, accuracy in results, and simple methods for diagnosis of the infectious diseases.

Increase in the incidence and prevalence of infectious diseases such as malaria, dengue, HIV, rise in healthcare expenditure, growing investments from public and private sectors for the development of new products, rising government support towards the adoption of point of care devices are expected to drive global infectious disease point of care diagnostics market over the forecast period. Moreover, the technological advancements in point of care diagnostic devices and introduction of home-based point of care devices are also anticipated to boost the infectious disease point of care diagnostics market. However, reluctance among the patients to change in existing diagnostic practices, stringent regulatory policies, and reimbursement issues might restrain the growth of global infectious disease point of care diagnostics market over the forecast timeframe.

The infectious disease point of care diagnostics market segmented based on product type, disease condition, prescription mode, and end users.

Based on product type, the infectious disease point of care diagnostics market segmented into the following:

- Infectious disease testing kits & Reagents

 - Hepatitis

 - HIV infection

 - Respiratory infections

 - Influenza

 - Sexually-transmitted diseases (STDs) infection

 - Others

- Haematology testing kits

- Urinalysis Testing Kits

- Others

Based on disease condition, the infectious disease point of care diagnostics market segmented into the following:

- Bacterial Infection

- Fungal infection

- Viral Infection

- Cardiovascular infection

- GI infections

Sexually transmitted disease

CNS infections

Other

Based on prescription mode, the infectious disease point of care diagnostics market segmented into the following:

Over-the-counter (OTC) Testing Kits

Prescription-based Testing Kits

Based on end-user, the infectious disease point of care diagnostics market segmented into the following:

Professional diagnostic centres

Hospitals

Outpatient healthcare Setting

Homecare

Others

The global infectious disease point of care diagnostics market is in the flourishing stage as several local and international players are actively involved in the development of infectious disease point of care diagnostic devices. Increase in the prevalence of the deadly infectious disease will drive the growth of the global infectious disease point of care diagnostics market. For instance, according to World Health Organisation, global health observatory (GHO) data, in 2013, approximately 34-38 million people suffered from HIV infection worldwide. Launching of new products, approvals from various regulatory bodies, acquisitions and mergers, partnerships, collaborations, and joint ventures are expected to fuel the growth of global infectious disease point of care

diagnostics market over the forecast period. For instance, in January 2015, FDA has approved Alere for its first CLIA waiver for the nucleic acid-based test, Influenza A&B. Further Roche's CLIA waiver for Cobas Liat System and Strep A. By 2016, many systems received CLIA waivers from FDA including the Xpert Flu/RSV Xc by Cepheid's.

Geographically, global infectious disease point of care diagnostics market has been segmented into following regions Viz. North America, Latin America, Europe, Middle East & Africa and Asia-Pacific. North-America holds a key share in global infectious disease point of care diagnostics market is due to increase in the prevalence of infectious diseases especially in U.S. (according to UNAIDS, in 2012, about 1.3Mn patients were diagnosed with HIV within the U.S.). These statistics are likely to increase over the coming years if suitable treatment options are not provided in time. The European region is also a major region for the growth of global infectious disease point of care diagnostics market due to improved healthcare infrastructure, and increase in prevalence of bacterial and viral diseases (according to WHO European Region, at the end of 2015, about 13.3 Mn people live with chronic hepatitis B, an estimated 15 Mn people with hepatitis C, and more than 2 Mn people with HIV). Moreover, Asia-Pacific region holds a significant growth in infectious disease point of care diagnostics market owing to the high prevalence of infectious diseases, unhygienic environment, and huge investment opportunities due to increase in healthcare expenditure. Moreover, due to high prevalence and incidence of infectious diseases especially sexually transmitted disease and bacterial infections, and high population - the growth of global infectious disease point of care diagnostics market expected to fuel in the Asia-Pacific region.

Some of the players in the global infectious disease point of care diagnostics market are Cepheid Inc. (Danaher Corporation) (U.S.), Abbott Laboratories, Inc. (U.S.), F. Hoffmann La Roche Limited (Switzerland), Beckman Coulter, Inc. (U.S.), Siemens AG (Germany), Johnson & Johnson Services, Inc. (U.S.), Instrumentation Laboratory (U.S.), Becton, Dickinson and Company (U.S.), Alere Inc. (U.S.), Nova Biomedical (U.S.), Thermo Fisher Scientific Inc. (U.S.), and Quidel Corporation (U.S.) to name a few.

In 2014, in the cardiovascular space, Spartan Biosciences has received approval from Health Care Canada for its genetic test, Spartan RX CYP2C19 system

In 2014, Roche bought point of care molecular testing company iQuum for \$275 million and the potential for an additional \$175 million in milestone payments

REPORT OUTLINE:

The report provides granular level information about the market size, regional market share and forecast from 2017-2023

The report covers in-detail insights about the competitor's overview, key findings and their key strategies

The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry

The report tracks recent innovations, key developments and startup's details that are working in the industry

The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL INFECTIOUS DISEASE POINT OF CARE DIAGNOSTICS MARKET INTRODUCTION

2.1. Global Infectious Disease Point of Care Diagnostics Market– Taxonomy

2.2. Global Infectious Disease Point of Care Diagnostics Market–Definitions

2.2.1. End User

2.2.2. Product Type

3. GLOBAL INFECTIOUS DISEASE POINT OF CARE DIAGNOSTICS MARKET DYNAMICS

3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

3.4. Trends

3.5. Global Infectious Disease Point of Care Diagnostics Market Dynamics – Factors Impact Analysis

3.6. Global Infectious Disease Point of Care Diagnostics Market– Recent Product Launches

4. GLOBAL INFECTIOUS DISEASE POINT OF CARE DIAGNOSTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

4.3. Market Opportunity Analysis

5. GLOBAL INFECTIOUS DISEASE POINT OF CARE DIAGNOSTICS MARKET FORECAST, BY PRODUCT TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Infectious Disease Testing Kits & Reagents

5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.1.3. Market Opportunity Analysis

5.2. Haematology Testing Kits

- 5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 5.2.3. Market Opportunity Analysis
- 5.3. Urinalysis Testing Kits
 - 5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
 - 5.3.3. Market Opportunity Analysis
- 5.4. Others
 - 5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
 - 5.4.3. Market Opportunity Analysis

6. GLOBAL INFECTIOUS DISEASE POINT OF CARE DIAGNOSTICS MARKET FORECAST, BY DISEASE CONDITION, 2012 - 2016 AND FORECAST, 2017 - 2023

- 6.1. Bacterial Infections
 - 6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
 - 6.1.3. Market Opportunity Analysis
- 6.2. Fungal Infections
 - 6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
 - 6.2.3. Market Opportunity Analysis
- 6.3. Viral Infections
 - 6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
 - 6.3.3. Market Opportunity Analysis
- 6.4. Cardiovascular Infections
 - 6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
 - 6.4.3. Market Opportunity Analysis
- 6.5. GI Infections
 - 6.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
 - 6.5.3. Market Opportunity Analysis
- 6.6. Sexually Transmitted Disease
 - 6.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
 - 6.6.3. Market Opportunity Analysis

6.7. CNS Infections

6.7.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

6.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.7.3. Market Opportunity Analysis

6.8. Others

6.8.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

6.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.8.3. Market Opportunity Analysis

7. GLOBAL INFECTIOUS DISEASE POINT OF CARE DIAGNOSTICS MARKET FORECAST, BY PRESCRIPTION MODE, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Over-the-counter (OTC) Testing Kits

7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.1.3. Market Opportunity Analysis

7.2. Prescription-based Testing Kits

7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.2.3. Market Opportunity Analysis

8. GLOBAL INFECTIOUS DISEASE POINT OF CARE DIAGNOSTICS MARKET FORECAST, BY END USER, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. Professional Diagnostic Centers

8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.1.3. Market Opportunity Analysis

8.2. Homecare

8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.2.3. Market Opportunity Analysis

8.3. Others

8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.3.3. Market Opportunity Analysis

9. GLOBAL INFECTIOUS DISEASE POINT OF CARE DIAGNOSTICS MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

9.1. North America

9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

9.1.3. Market Opportunity Analysis

9.2. Europe

9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

9.2.3. Market Opportunity Analysis

9.3. Asia-Pacific

9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

9.3.3. Market Opportunity Analysis

9.4. Latin America

9.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

9.4.3. Market Opportunity Analysis

9.5. Middle East and Africa

9.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

9.5.3. Market Opportunity Analysis

9.6. Global Infectious Disease Point of Care Diagnostics Market- Opportunity Analysis Index - By Product Type, By Disease Condition, By Prescription Mode, By End User, and Region, 2017 – 2023

10. NORTH AMERICA INFECTIOUS DISEASE POINT OF CARE DIAGNOSTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

10.1.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.1.1. Infectious Disease Testing Kits & Reagents

10.1.1.1.1. Hepatitis

10.1.1.1.2. HIV Infection

10.1.1.1.3. Respiratory Infections

10.1.1.1.4. Influenza

10.1.1.1.5. Sexually-Transmitted Diseases (STDs)

10.1.1.1.6. Others

10.1.1.2. Haematology Testing Kits

10.1.1.3. Urinalysis Testing Kits

10.1.1.4. Others

10.1.2. Disease Condition Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.2.1. Bacterial Infections

10.1.2.2. Fungal Infections

10.1.2.3. Viral Infections

10.1.2.4. Cardiovascular Infections

10.1.2.5. GI Infections

10.1.2.6. Sexually Transmitted Disease

10.1.2.7. CNS Infections

10.1.2.8. Other

10.1.3. Prescription Mode Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.3.1. Over-The-Counter (OTC) Testing Kits

10.1.3.2. Prescription-based Testing Kits

10.1.4. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.4.1. Professional Diagnostic Centres

10.1.4.1.1. Hospitals

10.1.4.1.2. Outpatient Healthcare Setting

10.1.4.2. Homecare

10.1.4.3. Others

10.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

10.1.5.1. U.S.

10.1.5.2. Canada

10.1.6. North America Infectious Disease Point of Care Diagnostics Market- Opportunity Analysis Index - By Product Type, By Disease Condition, By Prescription Mode, By End User, and Country, 2017 – 2023

10.1.7. North America Infectious Disease Point of Care Diagnostics Market Dynamics – Trends

11. EUROPE INFECTIOUS DISEASE POINT OF CARE DIAGNOSTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

11.1.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.1.1.1. Infectious Disease Testing Kits & Reagents

11.1.1.1.1. Hepatitis

- 11.1.1.1.2. HIV Infection
- 11.1.1.1.3. Respiratory Infections
- 11.1.1.1.4. Influenza
- 11.1.1.1.5. Sexually-Transmitted Diseases (STDs)
- 11.1.1.1.6. Others
- 11.1.1.2. Haematology Testing Kits
- 11.1.1.3. Urinalysis Testing Kits
- 11.1.1.4. Others
- 11.1.2. Disease Condition Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
 - 11.1.2.1. Bacterial Infections
 - 11.1.2.2. Fungal Infections
 - 11.1.2.3. Viral Infections
 - 11.1.2.4. Cardiovascular Infections
 - 11.1.2.5. GI Infections
 - 11.1.2.6. Sexually Transmitted Disease
 - 11.1.2.7. CNS Infections
 - 11.1.2.8. Other
- 11.1.3. Prescription Mode Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
 - 11.1.3.1. Over-The-Counter (OTC) Testing Kits
 - 11.1.3.2. Prescription-based Testing Kits
- 11.1.4. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
 - 11.1.4.1. Professional Diagnostic Centres
 - 11.1.4.1.1. Hospitals
 - 11.1.4.1.2. Outpatient Healthcare Setting
 - 11.1.4.2. Homecare
 - 11.1.4.3. Others
- 11.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
 - 11.1.5.1. Germany
 - 11.1.5.2. UK
 - 11.1.5.3. France
 - 11.1.5.4. Spain
 - 11.1.5.5. Italy
 - 11.1.5.6. Russia
 - 11.1.5.7. Poland
 - 11.1.5.8. Rest of Europe

11.1.6. Europe Infectious Disease Point of Care Diagnostics Market- Opportunity Analysis Index - By Product Type, By Disease Condition, By Prescription Mode, By End User, and Country, 2017 – 2023

11.1.7. Europe Infectious Disease Point of Care Diagnostics Market Dynamics – Trends

12. ASIA-PACIFIC INFECTIOUS DISEASE POINT OF CARE DIAGNOSTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

12.1.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.1.1. Infectious Disease Testing Kits & Reagents

12.1.1.1.1. Hepatitis

12.1.1.1.2. HIV Infection

12.1.1.1.3. Respiratory Infections

12.1.1.1.4. Influenza

12.1.1.1.5. Sexually-Transmitted Diseases (STDs)

12.1.1.1.6. Others

12.1.1.2. Haematology Testing Kits

12.1.1.3. Urinalysis Testing Kits

12.1.1.4. Others

12.1.2. Disease Condition Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.2.1. Bacterial Infections

12.1.2.2. Fungal Infections

12.1.2.3. Viral Infections

12.1.2.4. Cardiovascular Infections

12.1.2.5. GI Infections

12.1.2.6. Sexually Transmitted Disease

12.1.2.7. CNS Infections

12.1.2.8. Other

12.1.3. Prescription Mode Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.3.1. Over-The-Counter (OTC) Testing Kits

12.1.3.2. Prescription-based Testing Kits

12.1.4. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.4.1. Professional Diagnostic Centres

12.1.4.1.1. Hospitals

- 12.1.4.1.2. Outpatient Healthcare Setting
- 12.1.4.2. Homecare
- 12.1.4.3. Others
- 12.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
 - 12.1.5.1. Japan
 - 12.1.5.2. China
 - 12.1.5.3. India
 - 12.1.5.4. ASEAN
 - 12.1.5.5. Australia & New Zealand
 - 12.1.5.6. Rest of Asia-Pacific
- 12.1.6. Asia-Pacific Infectious Disease Point of Care Diagnostics Market- Opportunity Analysis Index - By Product Type, By Disease Condition, By Prescription Mode, By End User, and Country, 2017 – 2023
- 12.1.7. Asia-Pacific Infectious Disease Point of Care Diagnostics Market Dynamics – Trends

13. LATIN AMERICA INFECTIOUS DISEASE POINT OF CARE DIAGNOSTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

- 13.1.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
 - 13.1.1.1. Infectious Disease Testing Kits & Reagents
 - 13.1.1.1.1. Hepatitis
 - 13.1.1.1.2. HIV Infection
 - 13.1.1.1.3. Respiratory Infections
 - 13.1.1.1.4. Influenza
 - 13.1.1.1.5. Sexually-Transmitted Diseases (STDs)
 - 13.1.1.1.6. Others
 - 13.1.1.2. Haematology Testing Kits
 - 13.1.1.3. Urinalysis Testing Kits
 - 13.1.1.4. Others
- 13.1.2. Disease Condition Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
 - 13.1.2.1. Bacterial Infections
 - 13.1.2.2. Fungal Infections
 - 13.1.2.3. Viral Infections
 - 13.1.2.4. Cardiovascular Infections

13.1.2.5. GI Infections

13.1.2.6. Sexually Transmitted Disease

13.1.2.7. CNS Infections

13.1.2.8. Other

13.1.3. Prescription Mode Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.1.3.1. Over-The-Counter (OTC) Testing Kits

13.1.3.2. Prescription-based Testing Kits

13.1.4. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.1.4.1. Professional Diagnostic Centres

13.1.4.1.1. Hospitals

13.1.4.1.2. Outpatient Healthcare Setting

13.1.4.2. Homecare

13.1.4.3. Others

13.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.1.5.1. Brazil

13.1.5.2. Mexico

13.1.5.3. Argentina

13.1.5.4. Venezuela

13.1.5.5. Rest of Latin America

13.1.6. Latin America Infectious Disease Point of Care Diagnostics Market- Opportunity Analysis Index - By Product Type, By Disease Condition, By Prescription Mode, By End User, and Country, 2017 – 2023

13.1.7. Latin America Infectious Disease Point of Care Diagnostics Market Dynamics – Trends

14. MIDDLE EAST & AFRICA INFECTIOUS DISEASE POINT OF CARE DIAGNOSTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

14.1.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

14.1.1.1. Infectious Disease Testing Kits & Reagents

14.1.1.1.1. Hepatitis

14.1.1.1.2. HIV Infection

14.1.1.1.3. Respiratory Infections

14.1.1.1.4. Influenza

14.1.1.1.5. Sexually-Transmitted Diseases (STDs)

14.1.1.1.6. Others

14.1.1.2. Haematology Testing Kits

14.1.1.3. Urinalysis Testing Kits

14.1.1.4. Others

14.1.2. Disease Condition Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

14.1.2.1. Bacterial Infections

14.1.2.2. Fungal Infections

14.1.2.3. Viral Infections

14.1.2.4. Cardiovascular Infections

14.1.2.5. GI Infections

14.1.2.6. Sexually Transmitted Disease

14.1.2.7. CNS Infections

14.1.2.8. Other

14.1.3. Prescription Mode Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

14.1.3.1. Over-The-Counter (OTC) Testing Kits

14.1.3.2. Prescription-based Testing Kits

14.1.4. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

14.1.4.1. Professional Diagnostic Centres

14.1.4.1.1. Hospitals

14.1.4.1.2. Outpatient Healthcare Setting

14.1.4.2. Homecare

14.1.4.3. Others

14.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

14.1.5.1. Gulf Cooperation Council (GCC) Countries

14.1.5.2. Israel

14.1.5.3. South Africa

14.1.5.4. Rest of MEA

14.1.6. MEA Infectious Disease Point of Care Diagnostics Market- Opportunity Analysis Index - By Product Type, By Disease Condition, By Prescription Mode, By End User, and Country, 2017 – 2023

14.1.7. MEA Infectious Disease Point of Care Diagnostics Market Dynamics – Trends

15. COMPETITION LANDSCAPE

15.1. Strategic Dashboard of Top Market Players

15.2. Company Profiles (Introduction, Financial Analysis, Drug & Service Offerings, Key Developments, Strategies, and SWOT Analysis)

- 15.2.1. Cepheid Inc. (Danaher Corporation) (U.S.)
- 15.2.2. Abbott Laboratories, Inc. (U.S.)
- 15.2.3. F. Hoffmann La Roche Limited (Switzerland)
- 15.2.4. Beckman Coulter, Inc. (U.S.)
- 15.2.5. Siemens AG (Germany)
- 15.2.6. Johnson & Johnson Services, Inc. (U.S.)
- 15.2.7. Instrumentation Laboratory (U.S.)
- 15.2.8. Becton, Dickinson and Company (U.S.)
- 15.2.9. Alere Inc. (U.S.)
- 15.2.10. Nova Biomedical (U.S.)
- 15.2.11. Thermo Fisher Scientific Inc. (U.S.)
- 15.2.12. Quidel Corporation (U.S.)

16. RESEARCH METHODOLOGY

17. KEY ASSUMPTIONS AND ACRONYMS

I would like to order

Product name: Global Infectious Disease Point of Care Diagnostics Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Product link: <https://marketpublishers.com/r/G936D8BECC7EN.html>

Price: US\$ 4,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G936D8BECC7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970